Evidence map›Paper›PMID 42274762›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [

Josef Zahner, Astrid Delker, Zachary Ells, Ana Antic Nikolic, Adrien Holzgreve, Sophie C Siegmund, Maximilian Tiling, Mathias J Zacherl, Elena Berg, Can D Aydogdu and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Josef Zahner *Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany.
Astrid Delker *Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany.
Zachary EllsDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany.
Ana Antic NikolicDepartment of Nuclear Medicine, University Hospital Augsburg, Augsburg, Germany.
Adrien HolzgreveDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany.
Sophie C SiegmundDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany.
Maximilian TilingDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany.
Mathias J ZacherlDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany.
Elena BergDepartment of Urology, LMU University Hospital, LMU Munich, Munich, Germany.
Can D AydogduDepartment of Urology, LMU University Hospital, LMU Munich, Munich, Germany.
Alexander DierksDepartment of Nuclear Medicine, University Hospital Augsburg, Augsburg, Germany.
Marcus UnterrainerDie Radiologie, Munich, Germany.
Guido BöningDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany.
Christian StiefDepartment of Urology, LMU University Hospital, LMU Munich, Munich, Germany.
Jeremie CalaisAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, USA.
Constantin LapaDepartment of Nuclear Medicine, University Hospital Augsburg, Augsburg, Germany.
Rudolf A WernerDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany.
Jozefina Casuscelli *Department of Urology, LMU University Hospital, LMU Munich, Munich, Germany. Jozefina.casuscelli@med.uni-muenchen.de.
Lena M Unterrainer *Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAndrogen receptor signaling inhibitors (ARSi) have significantly improved clinical outcomes in men with prostate cancer (PCa). Preliminary data suggest the potential for ARSi to enhance PSMA expression in patients with mCRPC. In this analysis, we present preliminary dosimetry results from mCRPC patients treated with either [

methodsThis retrospective analysis was performed at a single center, including 50 patients diagnosed with mCRPC who underwent their first cycle of [

resultsOverall, 148 tumor lesions were included in this analysis (median 3 lesions per patient). The median tumor absorbed dose was comparable between the Combination Group and the Control Group: [

conclusionIn this pilot cohort, concomitant ARSi therapy did not significantly enhance tumor absorbed doses in patients receiving [

Indexed as

Absorption, RadiationAndrogen Receptor AntagonistsDipeptidesHeterocyclic Compounds, 1-RingLutetiumProstatic Neoplasms, Castration-ResistantReceptors, AndrogenSignal TransductionAgedAged, 80 and overHumansMaleMiddle AgedProstate-Specific AntigenRadioisotopesRadiometryAndrogen Receptor AntagonistsDipeptidesHeterocyclic Compounds, 1-RingLutetiumLutetium-177lutetium (177Lu) vipivotide tetraxetanProstate-Specific AntigenPSMA-617RadioisotopesReceptors, AndrogenAbsorbed doseARSiDosimetryMHSPC

Identifiers

PMID42274762
PMCPMC13526123

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.